Related Experiment Video
Updated: Jul 7, 2026
04:22
Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
Published on: May 30, 2025
Pharmacological therapy for female sexual dysfunction: has progress been made?
Susan R Davis1, Esme A Nijland
1Women's Health Program, Department of Medicine, Monash University, Prahran, Victoria, Australia. Susan.Davis@med.monash.edu.au
Drugs
|February 9, 2008
Summary
Female sexual dysfunction (FSD) research faces challenges due to evolving definitions and lack of expert consensus. Androgen therapy shows promise for improving sexual experiences in postmenopausal women with low libido.
Area of Science:
- Reproductive endocrinology and sexual health research.
Background:
- Female sexual dysfunction (FSD) is complex, with ongoing revisions to definitions and models of female sexual functioning.
- Lack of expert consensus on FSD trial criteria and outcome measures impedes research progress and drug intervention evaluation.
Purpose of the Study:
- To review the current state of research in female sexual dysfunction.
- To highlight the therapeutic potential of androgen therapy for improving sexual experiences.
Main Methods:
- Review of evidence from randomized controlled trials (RCTs) investigating treatments for FSD.
- Analysis of preliminary data on androgen therapy in premenopausal and postmenopausal women.
Main Results:
- Randomized controlled trials demonstrate that androgen therapy enhances the quality of sexual experience for postmenopausal women experiencing low libido.
- Preliminary findings suggest potential benefits of androgen therapy for premenopausal women with similar conditions.
Conclusions:
- Androgen therapy is a viable option for improving sexual quality of life in postmenopausal women with hypoactive sexual desire disorder.
- Further research is warranted to confirm the efficacy of androgen therapy in premenopausal women with FSD.
Related Concept Videos
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...